drugset / Trial / NCT01456897

A Long-term Trial of OPC-34712 in Patients With Schizophrenia

NCT01456897

Phase 3 Completed 282 enrolled Otsuka Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To investigate the safety and efficacy of long-term administration of OPC-34712 in patients with schizophrenia.

Timeline

Start
2011-10
Primary completion
2015-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 1 mg Oral
Subject Brexpiprazole Small molecule 2 mg Oral
Subject Brexpiprazole Small molecule 3 mg Oral
Subject Brexpiprazole Small molecule 4 mg Oral

Indications